Quest Diagnostics Inc
NYSE:DGX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
123.78
163.89
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Quest Diagnostics Inc
Wall Street
Price Targets
DGX Price Targets Summary
Quest Diagnostics Inc
According to Wall Street analysts, the average 1-year price target for
DGX
is 175.12 USD
with a low forecast of 155.9 USD and a high forecast of 194.25 USD.
DGX Last Price Targets
Quest Diagnostics Inc
The latest public price target was made on Oct 23, 2024 by
Eric Coldwell
from
Robert W. Baird
,
who expects
DGX
stock to
rise by 19%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Eric Coldwell
Robert W. Baird
|
182
USD
Upside 19% |
2 months ago
Oct 23, 2024
|
Baird Upgrades Quest Diagnostics (DGX) to Outperform
StreetInsider
|
Patrick Donnelly
Citigroup
|
185
USD
Upside 21% |
2 months ago
Oct 23, 2024
|
Quest Diagnostics price target raised to $185 from $165 at Citi
TheFly
|
Stephanie Davis
Barclays
|
168
USD
Upside 10% |
2 months ago
Oct 23, 2024
|
Quest Diagnostics price target raised to $168 from $154 at Barclays
TheFly
|
|
Michael Cherny
Leerink Partners
|
165
USD
Upside 8% |
2 months ago
Oct 23, 2024
|
Quest Diagnostics (DGX) PT Raised to $165 at Leerink Partners
StreetInsider
|
Paige Meyer
CFRA
|
178
USD
Upside 16% |
2 months ago
Oct 22, 2024
|
CFRA Upgrades Quest Diagnostics (DGX) to Buy
StreetInsider
|
David MacDonald
Truist Financial
|
165
USD
Upside 8% |
2 months ago
Oct 7, 2024
|
Quest Diagnostics price target raised to $165 from $158 at Truist
TheFly
|
Ann Hynes
Mizuho Securities
|
160
USD
Upside 5% |
4 months ago
Jul 29, 2024
|
Quest Diagnostics (DGX) PT Raised to $160 at Mizuho
StreetInsider
|
|
Eric Coldwell
Robert W. Baird
|
154
USD
Upside 1% |
5 months ago
Jul 24, 2024
|
Quest Diagnostics price target raised to $154 from $153 at Baird
TheFly
|
|
David MacDonald
Truist Financial
|
158
USD
Upside 3% |
5 months ago
Jul 15, 2024
|
Quest Diagnostics price target raised to $158 from $150 at Truist
TheFly
|
|
Stephanie Davis
Barclays
|
144
USD
Downside 6% |
8 months ago
Apr 25, 2024
|
Quest Diagnostics price target raised to $144 from $138 at Barclays
TheFly
|
Unknown Analyst
Wells Fargo
|
140
USD
Downside 9% |
1 year ago
Feb 3, 2023
|
Wells Fargo Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $140
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is DGX's stock price target?
Price Target
175.12
USD
According to Wall Street analysts, the average 1-year price target for
DGX
is 175.12 USD
with a low forecast of 155.9 USD and a high forecast of 194.25 USD.
What is Quest Diagnostics Inc's Revenue forecast?
Projected CAGR
5%
For the last 8 years the
compound annual growth rate for
Quest Diagnostics Inc's revenue is
3%.
The projected
CAGR
for the next 4 years is
5%.
What is Quest Diagnostics Inc's Operating Income forecast?
Projected CAGR
11%
For the last 8 years the
compound annual growth rate for
Quest Diagnostics Inc's operating income is
2%.
The projected
CAGR
for the next 3 years is
11%.
What is Quest Diagnostics Inc's Net Income forecast?
Projected CAGR
11%
For the last 8 years the
compound annual growth rate for
Quest Diagnostics Inc's net income is
2%.
The projected
CAGR
for the next 4 years is
11%.
You don't have any saved screeners yet
